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Electrospray ionization mass spectrometry is used to compare the metal ion binding and
metal-mediated DNA binding of benzoxazole (1, 2, 3, 4) and benzimidazole (5) compounds
and to elucidate the putative binding modes and stoichiometries. The observed metal versus
non-metal-mediated DNA binding, as well as the specificity of DNA binding, is correlated
with the biological activities of the analogs. The ESI-MS spectra for the antibacterial
benzoxazole and benzimidazole analogs 4 and 5 demonstrated non-specific and non-metal-
mediated binding to DNA, with the appearance of DNA complexes containing multiple
ligands. The anticancer analog 2 demonstrates a clear preference for metal-mediated DNA
interactions, with an apparent selectivity for Ni2-mediated binding over the more physio-
logically relevant Mg2 or Zn2 cations. Complexation between DNA and the biologically
inactive analog 1 was not observed, either in the absence or presence of metal cations. (J Am
Soc Mass Spectrom 2004, 15, 1593–1603) © 2004 American Society for Mass SpectrometryThere has been tremendous growth in recent years inthe number and types of new DNA-interactivedrugs developed, with an emphasis on creating
drugs that have greater degrees of selectivity for specific
DNA sequences or DNA structures [1–10]. If the drugs
bind only to certain types of DNA or recognize cells that
contain specific types of DNA, then the drugs can interfere
with the transcription or replication of targetedDNA, thus
exerting their pharmacological activities [1–10]. The drugs
frequently bind to DNA in a noncovalent fashion, and
thus methods to examine the nature of the interactions,
the binding sites, and stoichiometry are needed. Electro-
spray ionization-mass spectrometry (ESI-MS) has been
used to examine noncovalent drug/DNA complexes that
are formed in solution and gently transported into the gas
phase [11–40]. ESI-MS gives direct information about the
stoichiometry of the noncovalent complexes, along with
information about sequence selectivity and binding affin-
ities, and it is proving to be a versatile way to screen new
drugs for their DNA binding properties. In this report, we
focus on the use of ESI-MS to evaluate several novel
benzoxazole and benzimidazole analogs that bind to
DNA.
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doi:10.1016/j.jasms.2004.07.015The bis(benzoxazole) natural product UK-1, a sec-
ondary metabolite isolated from Streptomyces, has been
shown to possess a potent anticancer activity toward a
variety of cancer and tumor-derived cells [41, 42] (see
Figure 1). In contrast, UK-1 was found to lack antibac-
terial activity against bacteria, yeast, and fungi. Previ-
ous studies have reported that UK-1 also binds a variety
of divalent metal cations and also binds DNA in a
metal-mediated manner in solution, in particular with
the Mg2 ion. The observation of metal-mediated DNA
binding by UK-1 may be associated with its ability to
serve as a catalytic inhibitor of human topoisomerase II
[42, 43], which in turn may be related to the anticancer
activity of this natural product [42]. We have previously
evaluated the metal-mediated DNA binding of UK-1
using electrospray ionization mass spectrometry, in
which complexes of the type [ds  UK-1  metal]n
were detected for solutions containing self-complemen-
tary oligodeoxynucleotides that formed duplexes (ds),
and either Ni2, Co2, or Zn2 cations [32].
Several simplified analogs of UK-1, various benzox-
azole and benzimidazole compounds (Figure 1), have
been prepared to investigate the basic structural re-
quirements for metal ion binding, and to compare the
antibacterial versus anticancer cytotoxicity activities of
these analogs relative to that of UK-1 [42]. Of the
analogs included in this study, 4 and 5 displayed a
modest antibacterial activity against Staphylococcus au-
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trast, one of the analogs, 2, displayed a potent cytotox-
icity against several cancer cell lines at a level
comparable to UK-1 itself, although no significant anti-
bacterial activity against S. aureus was observed [42].
In the present study, electrospray ionization mass
spectrometry is used to detect noncovalent complexes
containing oligodeoxynucleotides and the benzoxazole
or benzimidazole analogs and to compare the metal ion
binding and metal-mediated DNA binding with the
known antibacterial and anticancer activities of the
analogs. In each case, the observed metal versus non-
metal-mediated DNA binding, as well as the specificity
of DNA binding, is correlated with the biological activ-
ities of the analogs. Overall, the results for these exper-
iments demonstrate that ESI-MS can be an efficient tool
for screening DNA-interactive compounds, including
the rapid determination of complex stoichiometries and
binding specificities.
Experimental
Chemicals
The synthetic UK-1 analogs 2, 4, and 5were prepared as
previously reported [42]. 1was purchased from Aldrich
(Milwaukee, WI) and used without further purification.
Methyl 2-(2=-hydroxyphenyl)-benzoxazole-7-carboxy-
late (3) was prepared by a modification of our previ-
ously reported benzoxazole synthesis [42]. The syn-
thetic details for the latter are available as
supplementary information.
Ammonium salts of HPLC-purified self-complemen-
tary oligodeoxynucleotides (ODNs) were purchased
from TriLink Biotechnologies Inc. (San Diego, CA),
custom synthesized on the 1.0 mol scale with purifi-
cation by HPLC in an ammonium acetate buffer. An-
nealing was performed in 1 M ammonium acetate by
heating to 90 °C for ten min, followed by slowly cooling
to room temperature over 8 h. Solutions containing
equimolar concentrations (25 M each) of one analog,
Figure 1. Structures of benzoxazole and benzimidazole li-
gands.one ODN, and one metal salt (where applicable) wereprepared in spray solvents containing 50% methanol in
water with 50 mM ammonium acetate, and allowed to
equilibrate at room temperature at nominally 6.5 pH
prior to analysis. The metal salts were purchased from
Aldrich Chemical.
Methods
Electrospray ionization mass spectra of the solutions
were collected with a Finnigan LCQ Duo ion trap mass
spectrometer (San Jose, CA) equipped with an electro-
spray ionization source operated in the negative ioniza-
tion mode with an electrospray voltage of 4 kV. The
instrument response was optimized for maximum
transmission of the bare ODN duplex ion using the
autotune feature of the mass spectrometer. The analyte
solution was introduced into the instrument by direct
infusion at a flow rate of 3 L/min. A heated capillary
temperature of 90 °C was used to ensure adequate
desolvation while minimizing in-source dissociation of
the noncovalent complexes. The base pressure of the
trap was about 1.0  105 torr.
Cytotoxicity [44] and antimicrobial [42] assays were
undertaken as described previously. Details are avail-
able in the supplementary section.
Results and Discussion
The DNA binding activities of the UK-1 analogs shown
in Figure 1 were evaluated by ESI-MS to determine and
compare the stoichiometries and metal ion require-
ments of gas-phase complexes with what is known for
these compounds in solution. The results were also
compared with the observed antibacterial versus anti-
cancer activities of the analogs.
Complexation of DNA and UK-1 Analogs Without
Metals
A series of experiments were performed in which
ESI-MS was used to evaluate the complexation between
the UK-1 analogs and self-complementary oligode-
oxynucleotides (ODNs) in the absence of metals. The
use of self-complementary ODNs produces readily in-
terpretable mass spectra with peaks generally com-
posed of single ion species [16, 17]. The unambiguous
assignment of even charge state duplex ions cannot be
made due to overlap of the m/z ratios for duplex ions
and single-stranded ions of half the charge. However,
the m/z value and charge state can be indirectly deter-
mined from examination of the metal adduct peaks,
provided that sufficient resolution of these metal ad-
ducts from the parent is achieved. The charge states and
hence m/z values of complexes containing an odd
multiple of drug, metal, or drug plus metal can be
assigned unambiguously for even charge state com-
plexes due to non-overlappingm/zwith the correspond-
ing single-strand complexes.
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self-complementary oligodeoxynucleotide 5=-GC-
GAATTCGC-3= sprayed from a solution containing 25
M DNA in 25% methanol and 50 mM ammonium
acetate exhibits an ion at m/z 1210 which can be unam-
biguously assigned as [ds 5H]5 due to its odd charge
state (see Figure 2a). However, the even charge state for
the ion at m/z 1513 indicates this ion could represent
either the [ss  2H]2 or [ds  4H]4 species, or
possibly a mixture of the two. Likewise, the ion at m/z
1008 could be [ss  3H]3 or [ds  6H]6, although
expansion of this ion and examination of the sodium
adduct satellite peaks suggests that the identity is [ss 
3H]3. Although apparent duplex ions could result
from non-specific aggregation of single strands during
the electrospray process, this has previously been
shown to be minimized or eliminated under similar
solvent conditions and ODN concentrations as was
used in this study [16, 17]. Thus, for the studies pre-
sented here, the duplex DNA peaks observed in the
electrospray mass spectra are assumed to result from
specific association of the self-complementary strands.
Two of the analogs in Figure 1, 4 and 5, have
previously been shown to exhibit modest antibacterial
activities against two strains of S. aureus, but lack any
significant cytotoxicities against four cancer cell lines
[42]. Although the specific antibacterial mechanisms of
these analogs are unknown, inhibition of bacterial gy-
rase consequent upon binding to either DNA alone or to
Figure 2. ESI-mass spectra for solutions contai
(d) 5 analogs.the DNA-gyrase complex is suspected, probably in amanner similar to what has been proposed for the
quinolone class of antibiotics [45–48].
Solutions containing one self-complementary duplex
ODN and one analog were prepared in 25% methanol
containing 50 mM ammonium acetate, and mass spectra
were collected in the negative ion mode. As shown in
Figure 2 for solutions containing 5=-GCGAATTCGC-3=
and each analogue, a distribution of complexes of both
4 and 5 charge states and containing from one to
four drug molecules per DNA duplex were detected in
modest abundance for each of the antibiotic 4 and 5
analogs (Figure 2c and d, respectively). Based on exper-
iments in which the concentration of the drug ligand
was increased or decreased by a factor of five relative to
the fixed concentration of DNA (data not shown), the
total number of bound drugs was found to be depen-
dent upon the overall drug:DNA ratio, indicative of
intercalative or non-specific binding without any well-
defined stoichiometry.
The lack of a well-defined DNA binding stoichiom-
etry by the antibiotic analogs is reminiscent of results
reported by Gabelica et al. for drug-DNA complexes
containing known intercalators such as ethidium bro-
mide, amsacrine, and ascididemin [16]; as well as Kapur
et al. for the more complex intercalators daunomycin
and nogalamycin [36]. In the study by Gabelica, the
DNA-binding modes observed in the gas-phase for
ethidium bromide, amsacrine, and ascididemin exhib-
ited the non-specific multiple-drug binding which par-
5=-GCGAATTCGC-3= and (a) 1, (b) 2, (c) 4, andningallels the binding behaviors observed in solution [16].
ontai
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ligand polarity, including ligand charge, and thus the
observed binding pattern could simply be an artifact of
the electrospray process. The peak distribution patterns
reported by Kapur et al. for daunomycin and nogala-
mycin were interpreted as following the neighbor ex-
clusion principle predicted for intercalators, in which
one drug molecule is inserted between every other base
pair in the duplex DNA [36].
In contrast to the results described above for the
antibiotic analogs, spectra collected for solutions con-
taining the same ODN and the inactive analog 1 or 3 or
the anticancer analog 2 showed no detectable drug-
DNA complexes under identical ESI-MS and spray
solvent conditions. Representative ESI-mass spectral
results are shown in Figure 2a and c for the duplex
ODN with 1 and 2, respectively (similar data for 3 is not
shown). Thus, the 1, 2, and 3 compounds are useful as
negative controls for monitoring electrospray-induced
artifacts such as aggregation or random electrostatic
binding.
Although the specific DNA binding mode or modes
for the antibacterial analogs cannot be unambiguously
determined from these results, it seems reasonable that
the benzyl substituents must contribute to the observed
binding behavior, possibly by additional stabilization of
the complexes through ring stacking or partial insertion
of the benzyl groups between DNA base pairs. Al-
though these results suggest an intercalative binding
mode, other modes including minor or major groove
binding, or a possible mixture of groove and intercala-
tive modes, cannot be ruled out. Results from recent
spectroscopic and molecular modeling studies by Lee et
al. have indicated a mixed binding mode incorporating
both groove binding and partial intercalation for inter-
actions between the quinolone antibiotic norfloxacin
and DNA [49, 50].
For comparison, solutions containing the same self-
complementary 10-mer 5=-GCGAATTCGC-3= and nor-
floxacin were prepared, and mass spectra collected
Figure 3. ESI-mass spectrum of solution cunder the same conditions as for the analogs describedabove. The spectrum in Figure 3 shows a nearly iden-
tical peak distribution as observed for the 4 and 5
antibiotic analogs. In contrast, spectra for solutions
containing the quinolone antibiotic nalidixic acid,
which exhibits a much lower antibacterial activity than
norfloxacin, exhibited no detectable formation of drug-
DNA complexes.
DNA and UK-1 Analogs
with Metals
Previous studies by Reynolds et al. and Kumar et al.
have implicated the role of divalent metal cation bind-
ing in the anticancer activities of UK-1 [41, 42]. In these
studies, both UK-1 and the anticancer analog 2 were
observed to form monomeric 1:1 complexes with diva-
lent metal cations in solution, in particular with the
physiologically relevant cations Mg2 and Zn2. In
addition, fluorescence and spectrophotometric experi-
ments have shown that the double-stranded DNA-
binding activity of UK-1 is ten-fold higher in the pres-
ence of Mg2, thus indicating that DNA binding by
UK-1 is metal mediated [41]. The metal-mediated bind-
ing of UK-1 to DNA has also been observed in our
laboratory by ESI-MS, although the results demonstrate
a clear preference for Ni2, Co2, and Zn2-mediated
binding, as opposed to Mg2 in which no detectable
(DNA  UK-1  Mg2) complexes were observed in
the electrospray mass spectra [32].
Given the implication for metal binding in the mech-
anism of action of UK-1 and the analogs, the metal-
mediated DNA-binding activities of the analogs was
also evaluated by electrospray ionization (Figure 4).
Solutions containing the antibacterial analogs (4 and 5)
and divalent metal cations, such as Ni2, produced no
obvious enhancement of DNA binding, nor significant
changes in peak distributions other than the presence of
low abundance species corresponding to metal-ad-
ning norfloxacin and 5=-GCGAATTCGC-3=.ducted ions (as expected). Therefore, this indicates a
ing 5
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bacterial analogs.
In contrast, the anticancer analog 2 showed a marked
enhancement in the formation of DNA-drug-metal
Figure 4. ESI-mass spectra of solutions contain
and (c) 1.
Figure 5. ESI-mass spectra of solutions containi
Ni2.complexes in the presence of Ni2 (Figure 4b), and a
modest enhancement in the presence of Cu2. Interest-
ingly, no significant binding was observed upon
ESI-MS analysis of solutions containing 2 and the more
=-GCGAATTCGC-3= and Ni2 with (a) 4, (b) 2,
-GCGAATTCGC-3= and 2with (a) Mg2 and (b)ng 5=
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with any of the other metals listed above (Figure 5). The
same experiments performed with the biologically in-
active analog 1 revealed a complete lack of DNA
binding, both in the presence and absence of divalent
metal cations, providing once again a negative control
for non-specific binding (Figure 4c). Since the 1 and 2
analogs differ only by the 4-carbomethoxy group in 2,
the DNA binding results indicate that this group is
obligatory for the observed metal-mediated binding
behavior.
The metal-mediated DNA complexation of 3 was
also examined by ESI-MS. DNA-3-metal complexes of
very low intensities were observed in the presence of
Mg2 or Ni2 (see Figure 6), indicating both less selec-
tivity and much lower affinity than that observed for 2.
The relative intensity of the DNA-3-Ni2 complexes is
about ten to forty times less than that observed for the
analogous 2 ligand.
NMR Studies
We have also carried out solution NMR studies of the
metal ion binding of 2 and its reversed analog 3.
Solutions of 2 in CD3OD/CDCl3 (100 mM) were pre-
pared and all 1H resonances were assigned by a com-
bination of COSY, HMBC, and HMQC NMR spectra.
The 2 solution was titrated with Mg(NO3)2·(H2O)6 in
Figure 6. ESI-mass spectra of solutions containi
Ni2.CD3OD (2.5 M) and the
1H NMR spectra recorded aftereach addition (Figure 7a). The initial addition of Mg2
(0.25 eq) caused a marked broadening of all the 1H
NMR resonances and shifts in specific peaks. Notably,
certain resonances, such as that due to the benzoxazole
C7 hydrogen (ca. 7.5 ppm), shifted downfield while
other resonances, such as those due to the 4-carbome-
thoxy group (ca. 3.7 ppm) shifted upfield. Further
additions of Mg2 resulted in upfield shifts of all
resonances, but in particular those due to the 4-carbo-
methoxy group and the ortho-hydroxyphenyl moiety
(ca. 6.7 and 6.8 ppm).
These solution studies support the role of the 4-car-
bomethoxy group in metal binding by 2 and also
implicate the benzoxazole moiety and the ortho-hy-
droxyphenyl substituent in metal ion coordination. The
complex relationship between 1H NMR resonance shifts
and Mg2 concentration may be due to the formation of
different metal ion complexes of different stoichiome-
tries during the titration experiment. Unfortunately,
attempts to shed light on potential differences in struc-
ture between the complexes formed with 2 and Mg2 or
Ni2 by NMR titrations are precluded by the paramag-
netic properties of the latter. NMR titrations of 2 with
various Cu2 salts also resulted in severe line broaden-
ing, presumably due to formation of paramagnetic Cu
species.
The role of the benzoxazole moiety in metal ion
coordination by 2 was explored by examining the Mg2
-GCGAATTCGC-3= and 3with (a) Mg2 and (b)ng 5=binding of 3, the reverse isomer of 2 in which the
esen
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changed. The 1H NMR spectral changes observed upon
addition of Mg2 to the isomeric benzoxazole analog 3
(Figure 7b) are distinct from those observed for 2. The
Figure 7. 1H NMR spectrum of (a) 2 in the pr1H NMR resonances for 3 are uniformly shifted upfieldin the presence of increasing concentrations of Mg2,
with no evidence for line broadening until an excess of
Mg2 is added. The apparent difference in the metal ion
complexation between the 2 and 3 must be due to the
ce of Mg2 and (b) 3 in the presence of Mg2.difference in the disposition of the benzoxazole N and
f a s
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moiety in Mg2 coordination by 2.
Metal Binding of 2 and 3
Given the marked dependence upon the presence of
divalent metal cations for binding between DNA and
analog 2, we also investigated the drug-metal inter-
actions by ESI-MS in order to gain insight into the
differences in drug-metal binding modes, which may
in turn provide clues to the observed gas-phase
metal-mediated DNA binding behavior described
above. These experiments were also done to provide
insight into the binding between 2 and metal cations
not accessible by NMR spectroscopy. The metal-
mediated binding properties of analog 2, and its
reverse analog 3, were evaluated in the absence of
DNA using similar spray solvent and instrument
conditions as used for the drug-DNA binding studies
above, but with spectra collected in the positive ion
mode.
Solutions containing 2 or 3 and one of several differ-
ent metal salts were prepared and analyzed by ESI-MS.
Two dominant ions were observed for solutions con-
taining 2 (or 3) with Mg2, Mn2, Fe2, Co2, Cu2,
Zn2 or Ni2: protonated 2 and the singly charged
dimer species assigned as [2 2HM2], in which
M2 is the metal ion (see Figure 8). There is no apparent
metal selectivity in the formation of the dimeric com-
plexes; however, collisional activated dissociation of the
complexes revealed a striking difference in the frag-
Figure 8. ESI-mass spectrum omentation pathways of the metal complexes (see Figure9). For the complexes containing 2 and Mg2, Mn2,
Fe2, Co2, or Zn2, the two major fragmentation
pathways involve loss of one neutral 2 ligand with
rapid adduction of water, or loss of methanol (Figure
9a). For the complexes containing 2 and Cu2 or Ni2,
the only dissociation pathway is the loss of a neutral 2
ligand with rapid adduction of water (from reaction
with traces of background water in the trap), and the
elimination of methanol is not observed (Figure 9b).
The fact that the methanol elimination pathway is
completely quenched for the Ni2 and Cu2 complexes
suggests a significant change in the structures of these
dimeric structures. The loss of methanol from the [2 
2  H  M2] dimers likely involves a methoxy group
from one ligand and a hydrogen from the second
ligand, thus requiring an intramolecular migration in
which the two moieties (methoxy and hydrogen) must
be in sufficiently close proximity to facilitate the elimi-
nation. In the Ni2 complexes, the two 2 ligands may be
rotated in such a way that the methanol loss can not
occur. Although these dimeric species are not necessar-
ily involved in the formation of the DNA complexes, it
does suggest that Ni2 coordinates to 2 in an unusual
way, and this unique Ni2 selectivity may be responsi-
ble for mediating the complexation to DNA.
Similar CAD studies were carried out for the dimer
containing the reverse analog, 3. For both the [2  3 
H  Mg2] and [2  3  H  Ni2] complexes, the
loss of methanol is never observed upon activation of
the complexes. Instead the dimeric complexes dissoci-
ate by elimination of one 3 ligand, with rapid adduction
olution containing 2 and Ni2.of water to the resulting product ions. The complete
2 
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phenolic hydroxyl group and methyl group are never in
sufficiently close proximity to facilitate the loss of
methanol from the dimeric complexes.
Biological Studies
As previously reported, UK-1 and the benzoxazole
analog 2 are cytotoxic to cancer cell lines, particularly
PC-3 prostate cancer cells (IC50  0.4 and 0.91 M,
respectively) [42]. Neither of these compounds are
active as antibacterial agents [42], whereas the benz-
imidazole 5 and benzoxazole 4 are weakly antibacterial
(IC50 S. aureus  102 and 43 M, respectively). The
cancer cell cytotoxicity and antibacterial activity of the
previously unreported UK-1 analog 3were determined.
Like UK-1 and 2, 3 is inactive against Staphylococcus
aureus and methicillin-resistant S. aureus at all test
concentrations, up to 185 M. 3 displayed only weak
cytotoxicty against PC-3 prostate cancer cells (IC50  47
M). This level of cytotoxicity is more than 50-fold less
than that of the isomeric benzoxazole 2, and over
100-fold weaker than the natural product UK-1. 3 was
also only weakly active against the colon cancer cell line
HT-29 (IC50  36 M), as compared to the isomeric
benzoxazole 2 (IC50  9.1 M). Thus, the cancer cell
cytotoxicity of these benzoxazole analogs of UK-1 is
strongly sensitive to their structural features, and mir-
rors their relative ability to form DNA-drug-metal
Figure 9. CAD mass spectrum of (a) (2 complexes.Conclusions
The results presented in this study demonstrate the use
of ESI-MS to evaluate the interactions between the UK-1
analogs and DNA, in particular to gain information on
the putative binding modes, stoichiometries, and metal
ion requirements. The ESI-mass spectra for the antibac-
terial benzoxazole and benzimidazole analogs 4 and 5
demonstrated non-specific and non-metal-mediated
binding to DNA, with the appearance of multiple-drug
peaks analogous to binding observed for the quinolone
antibiotic norfloxacin, and perhaps reminiscent of bind-
ing patterns observed for simple intercalators.
In contrast, ESI-MS of the DNA binding by the
anticancer analog 2 demonstrates a clear preference for
metal-mediated DNA interactions, with an apparent
selectivity for Ni2-mediated binding over the more
physiologically relevant Mg2 or Zn2 cations. No
gas-phase noncovalent complexes between DNA and
the biologically inactive analog 1 were detected, either
in the absence or presence of metal cations. Conse-
quently the 1 analog provides a useful negative control
compound for relating observed DNA binding by
ESI-MS and biological activity, as well as controlling for
random electrostatic DNA binding and electrospray
artifacts such as non-specific aggregation. Overall, the
observed binding and metal ion requirements for inter-
actions between DNA and the simpler UK-1 analogs
correlate with their known antibacterial versus antican-
H  Mg2) and (b) (2  2  H  Ni2).cer activities.
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